Ontology highlight
ABSTRACT: Background
Sacituzumab govitecan is an antibody-drug conjugate that delivers SN-38, an active metabolite of irinotecan, to the target molecule, trophoblast cell-surface antigen 2 (Trop-2). It is a promising drug for triple-negative breast cancer and is anticipated to be effective for luminal breast cancer. The efficacy of the agent relies on the expression of Trop-2 rather than its intracellular function. However, conditions that alter the Trop-2 expression have not been well investigated.Methods
We tested a range of clinically related treatments for their effect on Trop-2 expression in cultured breast cancer cell lines.Results
The expression level of Trop-2 differed among cell lines, independent of their subtypes, and was highly variable on treatment with kinase in
SUBMITTER: Zhu J
PROVIDER: S-EPMC9587948 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature